Power3 Medical’s (OTCBB: PWRM.OB) business focus is the development of commercial applications for their proprietary technologies. The scientific team is on the leading edge of the proteomics industry through their discovery of protein footprints, pathways, and mechanisms of disease. These discoveries are being used to develop screening and diagnostic tests for the early detection and treatment of disease. The protein biomarkers, drug targets, and diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer, neurodegenerative disease and drug resistance in cancer. The Company is in a strong competitive position with over 190 identified biomarkers and a state-of-the-art proteomics laboratory.
PWRM pursues an aggressive intellectual property strategy to protect its inventions and discoveries made on its own and with its collaborators. Power3 Medical works with key physician scientists at major medical research and treatment centers. With access to decisive human clinical samples and superior trade secret proteomic methodologies, the Company provides solutions to pressing challenges in diagnosis and treatment of patients and has concluded research agreements, technology license agreements, and filed provisional and utility patents.
Acacia Research Corporation (Nasdaq: ACTG) announced today that its subsidiary, Telematics Corporation, has entered into a patent license agreement with Navman Wireless Holdings LP.
Telematics’ patented technology generally relates to systems and methods for displaying mobile vehicle information on a map. This technology can be used in navigation and fleet management systems that combine wireless communication with GPS tracking and map displays.
Acacia Research’s subsidiaries partner with inventors and patent owners, license the patents to corporate users, and share the revenue. Acacia Research’s subsidiaries control over 150 patent portfolios, covering technologies used in a wide variety of industries.
Acorda Therapeutics, Inc. (Nasdaq: ACOR) recently announced that Ron Cohen, M.D., President and Chief Executive Officer, is the recipient of the New York Biotechnology Association (NYBA) “The Cures Start Here” Business Leader of the Year Award. The award is presented for outstanding service to the patient community and to NYBA.
“Under Dr. Cohen’s leadership, Acorda recently received FDA approval for AMPYRA™, which represents a significant contribution to the treatment of people with multiple sclerosis,” said Nathan Tinker, Ph.D., Executive Director of NYBA. “Acorda exemplifies the vibrancy of the New York biotechnology industry and NYBA is pleased to recognize Dr. Cohen for his dedication to helping people with neurological disease, and for his ongoing commitment to the growth of the biotechnology industry in New York.”
PDL BioPharma, Inc. (Nasdaq:PDLI) recenlty announced revenue guidance for the second quarter ended June 30, 2010 of approximately $120 million, as compared with actual results of $125.9 million for the second quarter of 2009. Included in second quarter 2010 guidance is $1.5 million earned on Eurodollar foreign currency hedging contracts that the Company initiated in January 2010. Included in actual results for the second quarter 2009 and not included in second quarter 2010 guidance are the second of two $12.5 million installment payments from Alexion and royalties of $18.9 million for sales of Synagis®. The Company does not anticipate receiving royalties for Synagis sales in the second quarter of 2010 due to the ongoing legal dispute with MedImmune.